This study investigates pancreatic ductal adenocarcinoma (PDAC). It focuses on using liquid biopsies to detect circulating tumor DNA (ctDNA) after treatment. The purpose is to assess if ctDNA can indicate residual disease and the risk of cancer returning.
The study evaluates the effectiveness of ctDNA tests in a clinical setting. It examines the relationship between ctDNA presence and patient outcomes, such as disease-free survival and overall survival.
- Who can participate: Adults 18 years or older with pancreatic ductal adenocarcinoma scheduled for curative surgery can participate. Those with hereditary pancreatic cancer or other recent cancers are excluded.
- Study details: Participants will have their blood sampled at specific times to check for ctDNA.
How understandable was the trial content above?
Hard to understand
Easy to understand